Blackstone announced the final close of its latest life sciences fund, Blackstone Life Sciences VI, at $6.3 billion, marking the largest private fund ever dedicated to the life sciences sector. The fund reached its hard cap and was oversubscribed, reflecting strong investor demand and confidence in the firm’s strategy.
The new fund is nearly 40 percent larger than its predecessor and builds on Blackstone’s expanding presence in life sciences investing since launching its dedicated platform in 2018. As of the fourth quarter of 2025, the platform manages approximately $15 billion in assets.
Blackstone Life Sciences focuses on investing across the lifecycle of companies and products in key sectors such as pharmaceuticals and medical technology. The firm partners with industry leaders to fund the development and commercialization of treatments and devices, including blockbuster medicines such as LEQVIO, AMVUTTRA, and IMBRUVICA, as well as devices like MiniMed Flex.
The platform has demonstrated a strong track record, achieving an 86 percent approval success rate for Phase III assets, outperforming industry averages. Its investments have contributed to 34 regulatory approvals of medicines and devices globally.
Over the past 12 months, the firm has committed nearly $2 billion in new investments, including partnerships with major pharmaceutical companies and strategic funding agreements across oncology, RNAi therapeutics, and other advanced treatment areas. These transactions highlight Blackstone’s role as a major capital provider in late-stage drug development and commercialization.
The firm noted that its ability to source, finance, and actively manage large-scale investments has positioned it as a leading participant in life sciences royalties and late-stage product financing.
KEY QUOTE:
“We are grateful to the BXLS VI investors for their strong support of our strategies and the firm’s enduring conviction in the life sciences. Our partnerships with global leaders have produced 34 regulatory approvals of innovative medicines and devices. This track record highlights how we work successfully with industry trailblazers to help bring their most important products to patients around the world.”
Nicholas Galakatos, Global Head Of Blackstone Life Sciences, Blackstone
